Reports Q3 revenue $25.2M, consensus $24.54M.”Akoya delivered strong financial performance in the third quarter with another record revenue quarter while maintaining operating expenses at a steady or reduced level, solidifying the path towards achieving positive cash flow,” explained Brian McKelligon, Chief Executive Officer of Akoya Biosciences. “We are executing on our plan to improve workflow throughput, with the ongoing 2.0 instrument field upgrades across the industry’s largest installed base and by expanding our menu of ready-to-use panels. Akoya is strategically positioned to scale spatial biology by setting the standard in the industry.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AKYA:
- Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
- Akoya Biosciences to showcase spatial biology 2.0 solutions
- Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023
- Akoya Biosciences price target lowered to $8 from $15 at Morgan Stanley
- Akoya Biosciences announces publication on ultrahigh-plex spatial phenotyping